Podcast appearances and mentions of Joe Quinn

Michael Healy-Rae, who’s Minister of State at the Department of Agriculture with responsibility for forestry, says trees should be planted on peatlands. Sinn Féin’s spokesperson for climate, the environment and energy Pa Daly says such proposals are ill-conceived and irresponsible. At the start of the interview, Minister of State Healy-Rae paid tribute to Joe Quinn, who died in a farm accident in Tahilla this week. Deputy Daly also offered his condolences to Mr Quinn’s family.

Blood-based biomarkers for dementia diagnosis are emerging and rapidly evolving. These fluid biomarkers should be used when the results will impact management decisions, including patient and family counseling, symptomatic therapies, and disease-modifying therapies. In this episode, Allison Weathers, MD, FAAN, speaks with Joseph F. Quinn, MD, FAAN, an author of the article “Fluid Biomarkers in Dementia Diagnosis,” in the Continuum® December 2024 Dementia issue. Dr. Weathers is a Continuum® Audio interviewer and associate chief medical information officer at the Cleveland Clinic in Cleveland, Ohio. Dr. Quinn is a professor in the Department of Neurology at Oregon Health & Science University in Portland, Oregon. Additional Resources Read the article: Fluid Biomarkers in Dementia Diagnosis Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Transcript Full interview transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Weathers: This is Dr Allison Weathers. Today, I'm interviewing Dr Joseph Quinn, author along with Dr Nora Gray, of Fluid Biomarkers in Dementia Diagnosis from the December 2024 Continuum issue on dementia. Welcome to the podcast and please introduce yourself to our audience. Dr Quinn: Sure. I'm Joe Quinn. I'm a neurologist at the medical school in Oregon, Oregon Health Science University, and I work in neurodegenerative disease, Alzheimer's disease, and Parkinson's disease.  Dr Weathers: Certainly some really weighty topics. But again, as I said, today we want to focus on a really fascinating one, the concept of fluid biomarkers in dementia diagnosis. And we'll perhaps get into monitoring of treatment as well. So, this search for reliable biomarkers in the diagnosis of dementia, certainly not a new topic, but you and your co-author Dr Nora Gray did a really fantastic job in the article right from the get-go, laying out the urgency around this now that there are FDA of treatments that depend on pathologic diagnosis. And it feels like they're more and more announced by the day. Even as I was preparing for this interview a few days ago, the FDA approval for donanemab was announced, with the news making every major media outlet. Well, there are several really critical points made by you both in the article. What do you feel is the most important clinical message of your article? What do you want our listeners to walk away with as their one key takeaway?  Dr Quinn: I think we still have the best evidence for CSF biomarkers, cerebrospinal fluid biomarkers, really making a diagnosis with some confidence. PET scans are available for visualizing amyloid and Tau now, but they're so expensive and they're not covered. So, the spinal tap information is what most of us around here really rely on when we want to be sure about what's going on. The blood tests are very promising, very exciting, but as you probably know, there's a lot of different opinions about this out there. Some people are sure that it's a done deal and that we now have a blood test for Alzheimer's disease. After I sent the article off, I opened up my issue of Neurology and there was an editorial saying these blood tests will never work. So, there's different ends of the spectrum on this and we tried to strike a balance with that. So they're very promising. I think before the article is due for revision, things are going to be different. But right now, spinal fluid is probably where we have the most confidence. Dr Weathers: I think that's a really solid takeaway to start our discussion with. And then, I think you both did really strike that very delicate balance in what is right now an area where, as I said, you know, things still are changing by the day. I know for our listeners who do subscribe, and I hope that most of them do, Table 9.1, clinically useful CSF biomarkers for the differential diagnosis of dementia, is one that I personally think I will frequently return to. You and Doctor Gray did just a wonderful job organizing these very complex concepts into an easy read and really powerful tool, especially for use at the bedside. Along the lines of knowing which biomarker to use, how frequently routine care are you ordering these tests on your patients? And do you anticipate this changing the media future? Is this another one of those things that by next week, we'll have a different kind of answer in how we use these tests? Dr Quinn: Yeah, as you said in your preliminary comments, the whole picture has been changed by the approval of these antibody therapies for Alzheimer's disease, lecanumab and just last week, donanemab. Prior to the approval of those two medications, I didn't use spinal fluid tests routinely, but I relied on them when I really needed to make a diagnosis with certainty of something really important hung in the balance. If we were trying to rule out some other treatable, more treatable problem. You know, for example, if it was a question of whether somebody primarily had a psychiatric problem or a neurodegenerative disease, this is something that would really allow me to objectify things. And- but that was a minority of people that I would see for dementia evaluation. You know, now that the two therapies are approved, I'm not actively engaged in administering those therapies very frequently but I can see already that the, the patients that I am discussing this with that spinal fluid is where we're probably going to rely for making a diagnosis of the amyloid burden in the in the living patient until PET scans are approved. If amyloid PET scans are- not approved, but covered by insurance, then those will probably replace the spinal fluid. So those tests in that table, A beta 42, tau, p-tau, one of them that's relatively new is this test for aggregated alpha-synuclein. Those I order with some frequency when I'm in those circumstances.  Dr Weathers: That's really helpful for our listeners to hear from an expert such as yourself and to think about as they encounter similar patients. Whenever discussing complex topics such as this one, I'm always curious about, what is the most common misconception or pitfall regarding the use of biomarkers for the diagnosis of Alzheimer's and other dementia that you encounter?  Dr Quinn: With respect to the blood biomarkers, you know, we were saying a moment ago that there's a lot of evidence available, but the jury is still out to some degree as to how reliable they are. And I think an important message with respect to those blood biomarkers is that they really are confounded by comorbidities. Remember, we're dealing with an elderly population, so comorbidities like hypertension and renal insufficiency and those kinds of things are relatively common and they can really throw off the blood biomarkers in a more dramatic way than cerebrospinal fluid biomarkers. The other fact, and I can't remember how well we cited this in the article, was that the blood biomarkers don't perform as well in underrepresented minorities. And you know, all of us are appropriately paying more attention to that problem in our practice of medicine. And for these blood biomarkers, that's a real issue. And whether the inferior performance in underrepresented groups is due to more comorbidity or just due to genetic differences is unclear at this time. So those are really important cautions. We mentioned the renal insufficiency and, I think, some of the other comorbidities, but it's a reason to really be careful with the blood biomarkers.  Dr Weathers: I think a really important point, especially again, kind of going back to what we were talking about at the beginning of our discussion, there's so much excitement around them. There's so much potential. People think we finally have that kind of silver bullet of diagnosis. So, I think really something to keep in mind.  What about in the use of their- in monitoring the efficacy of treatments?  Dr Quinn: So that's I think a little earlier in its history in terms of what biomarkers would be useful for monitoring. But the donanemab trial really relied on blood biomarkers as outcome measures and really showed some interesting phenomena. One of them was that plasma neurofilament light, which is all the rage now and all over neurology, people are measuring plasma neurofilament light. It's a nonspecific marker of neuronal damage that makes it out into the serum. So, you can measure it in serum and detect CNS damage in the serum. And intuitively, you would think that would be a good measure of efficacy, but in terms of detecting a treatment effect with donanemab, it didn't perform very well. Conversely, GFAP, which is a marker of astrocyte activation, which I would not have predicted was going to be a sensitive marker for treatment efficacy, performed well in at least the donanemab trial. So, I think it's early in the history of using these markers as outcome measures in clinical trials. And I think we're going to continue to learn as each therapy comes along and as these things come to pass.  Dr Weathers: Don't make any assumptions yet? Would that be a good way to sum that up?  Dr Quinn: I think that's, yes. I think that's very fair that that we have to be careful about these things.  Dr Weathers: OK. So, in summary, I think, does it sound like it's fair to say that the pitfall might be to say it's too early to make any assumptions or any conclusions quite yet? Dr Quinn: That's right. And, and I think, you know, we're going to need to monitor these therapies. I think all of us in neurology have become very accustomed to how you do that in multiple sclerosis, right? We've got MRI scans to be used to monitor therapy, maybe NFL is going to be an appropriate assay there as well. But, you know, there we've all had the experience of a chronic disease and seeing how well your therapy is doing, changing therapy if it fails. So, we're absolutely going to need those things in in Alzheimer's disease and other neurodegenerative diseases, but it's a little early for us to be sure exactly what the right measures are to make those important decisions. Dr Weathers: And a lot more work to be done for sure. As I mentioned, this is a topic of such great interest and I know, you know, certainly most of our listeners are neurologists or people in our world, medical students and trainees. I know I have one regular nonneurologist listener, my father. He really gets a kick out of listening to my interviews. Even though he is a retired sales manager from IBM and most of the time the topics of discussion are pretty different from his usual favorite podcasts. But this one he will be particularly interested in and I'm sure I will get a list of questions about, particularly because my grandfather unfortunately had Alzheimer's disease. So, I'm sure one of his questions will be about the use of these biomarkers in asymptomatic patients. How do you counsel family members of patients when they inquire about the use of biomarkers for that youth case? What is their utility in presymptomatic testing? Dr Quinn: We know from studies like the Alzheimer's disease neuroimaging initiative and other biomarker studies that some of these markers will be sensitive to pathology. Even in asymptomatic people, that pathology appears long before people develop symptoms. Despite that, I don't recommend that asymptomatic people get any of the testing right now because we do not have evidence that early intervention at the completely asymptomatic stage is valuable. And those clinical trials are underway. There are trials underway right now for people who don't even meet the memory deficit required to have a diagnosis of mild cognitive impairment, people who are entirely cognitively intact, but who on one biomarker study or another have evidence of pathology burden. And the interventions are being started early. And in a few years, we'll know the answer to that. Right now, for somebody to find out that they have pathology without any ability to act on it, I think is not valuable. So, I discourage people from pursuing that.  Dr Weathers: And that is really important guidance. Thank you. I know you have, as you mentioned, a beginning in a really diverse neurologic background with expertise, as you said, not only in dementia, but also in Parkinson's disease. And you didn't even mention this, but I know expertise in stroke as well, but your research has been primarily in Alzheimer's. What drew you to dementia and to this specific the aspect of it? How did you become an expert in biomarkers?  Dr Quinn: Well, I'll start with the dementia part. So, you know, I was always just interested intuitively in trying to understand how, you know, the brain mediates the mind. So as an undergraduate, I got started working in a lab that was working on the cholinergic system in the brain, which was still being sorted out at that time. It is important in Alzheimer's disease, but it was really where the focus was. And that's what got me interested in Alzheimer's disease, which incidentally is what got Alzheimer interested in Alzheimer's disease. You know, he was very interested in trying to find the biological footprints of all these different neurological and psychiatric diseases. And he usually came up empty-handed until he came across the patient with Alzheimer's disease where there were actual footprints in the brain that he thought was pointing towards what was going on. And we're still wondering about that a hundred years later, I guess that's how I got interested in dementia and Alzheimer's disease. I think I have always spent part of my time as a clinician. I think that's what got me interested in biomarkers, that this problem has always been there that, you know, we've got quite, you know, research criteria for making diagnosis and all that sort of thing. But we've really needed some biological evidence to help us firm this up even before the availability of the therapies. And that's what got me interested in- I'm making another point. I thought that computer research biomarkers are going to help point me towards the causes of the disease, and unfortunately that part hasn't entirely panned out. We've got some research in that area on micro-RNA biomarkers that maybe will bear some fruit down the road, but that's been a tougher, tougher nut to crack. Dr Weathers: But it's so incredibly important work. Well, this has been wonderful. I really enjoyed our conversation, and I always like to end on a hopeful note. What developments in the biomarker space are coming on the horizon are you most excited about? Dr Quinn: I'm hoping that these biomarkers that allow us to evaluate disease efficacy, blood biomarkers that don't require extraspinal taps and that sort of thing. I hope that all comes to pass. And I do think that there is a lot of research underway looking at biomarkers in a novel way that I think could help point us to new targets for therapy, things that you and I haven't even thought of yet. Those are the two things. I guess you asked me for one, I gave you two.  Dr Weathers: Oh I think very fair. I agree. Both of those would certainly be wonderful and, and I'm excited as well. Well, thank you, Dr Quinn, for taking the time to speak with me this evening.  Dr Quinn: A pleasure. Thank you for having me. Thank you for inviting me to do the piece. It was really a great experience.   Dr Weathers: Again, today I've been interviewing Dr Joseph Quinn, who's written with Doctor Nora Gray on fluid biomarkers and dementia diagnosis. This article appears in the December 2024 Continuum issue on Dementia. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

From Danielle's female gaze pick of the week to guest on this week's episode. e have none other than Louisana's own Cajun Dan himeself! From wrestling gators, to the best spots for food in New Orleans, and his rise to TikTok fame, we get to know Dan a little more and our boy does not disappoint!

This week we're ‘following the fin' with Louth native, Joe Quinn, who has been based in Mayo for the last fifty years, and is a well-known international angler who has fished for salmon, sea trout and his first love, brown trout. We talk to Joe about brown trout on Lough Conn, night time sea trout fishing, why he ditched the salmon rod over twenty years ago and find out some special fishing stories from New Zealand. Plus, he tells us how a GoPro retirement present to himself has seen him set up an ever-growing YouTube channel at:https://www.youtube.com/@JoeQuinnFollow_the_fln  Keep up to date with all the latest Ireland on the Fly on https://www.IrelandontheFly.com and get regular updates on https://Instagram.com/IrelandontheFly.

You wanna know what's crazy...manifestation. It's crazy what can happen when you put something out into the universe. This is exactly what Laura and Danielle talk about today. They also touch on how celebrities/artists...don't owe us anything.

Monumental Results!Joe Quinn, CHRO at Vision Technologies, reveals his top strategy for achieving extraordinary success in both his personal and professional life.A passionate life-long learner, Joe's journey is nothing short of inspiring.His first appearance on Lead the Team was packed with invaluable tips, practical gadgets, and a contagious enthusiasm that left me and our listeners craving more.And now, he's back, delivering even more transformative insights......plus, he's lost 25 pounds! Joe Quinn's return is a testament to his relentless dedication and the powerful impact of his strategies.Don't miss out on this electrifying episode!LinkedIn Profile https://www.linkedin.com/in/joe-quinnCompany Link: http://www.visiontechnologies.com/What You'll Discover in this Episode:A Book that Accelerated his Performance.The Ring that Tracks Everything.Losing 25 lbs as “Joe Natural”.AI Hiring Tips.A Yogurt Recipe for Power.Customer Service Hack from the Ritz..What He Learned from Tony Robbins.A Top Stock Pick.Quotes:"If you gotta goal, you've gotta measure it.'-----Connect with the Host, #1 bestselling author Ben FanningSpeaking and Training inquiresSubscribe to my Youtube channelLinkedInInstagramTwitter

Arguably the most unhinged episode the girls have released to date. CAN WE TALK ABOUT ESQUIRE SINGAPORE?! Also why are all of joes characters so tragic?

A few changes to announce! We cover Fan Expo New Orleans. The life altering phenomenon that is Saltburn and Joe's attendance at FanExpo Portland!

One TraitJoe Quinn, CHRO and SVP at Vision Technologies, shares the ONE thing to prioritize over ALL else when hiring. He's been leading organizations for over 30 years and narrowed it down to the true identifier of success for you, them, and the entire team.I've started keeping this in mind when building my team, and it's made a BIG difference.You'll hear Joe's incredible personal growth journey where he shares his top executive meditation tip and how working with Tony Robbins transformed his career.Truly inspiring stuff including:What it's like moving into an NBA Legend's house.The health benefits of an infrared sauna, hot tubs, and cold plunge.What happened when he walked on hot coals with 20,000 people.How to Beat the Market When You Invest.Tips for becoming a Board Member.—-----LinkedIn Profile https://www.linkedin.com/in/joe-quinnCompany Link: http://www.visiontechnologies.com/What You'll Discover in this Episode:What it's like moving into an NBA Legend's house.Executive daily routine optimization tips.The health benefits of an infrared sauna, hot tubs, and cold plunge.Go-to Non-fictionMeditation Benefits for Leaders.What he Learned from Tony Robbins.What happens when you walk on hot coals with 20,000 people.The “48 Laws of Power”.A powerful way to accelerate someone's career.How he Beats the Market When he Invests.Tips for becoming a Board Member.Resources:Dr. Joe Dispenza Mindset, Carol Dweck48 Laws of Power, Robert Greene-----Connect with the Host, #1 bestselling author Ben FanningSpeaking and Training inquiresSubscribe to my Youtube channelLinkedInInstagramTwitter

On this episode of Our American Stories, our next story comes to us from a listener in West Virginia. Here's Joe Quinn with his story. Support the show (https://www.ouramericanstories.com/donate)See omnystudio.com/listener for privacy information.

You remember that scene.... the one that made you realize you actually didn't think boys had cooties anymore. The girls unpack their top three moments throughout their childhood that had them feeling all sorts of ways

I mean... Let's not pretend we didn't know we'd go back to talking about Joe. HOARD HAS MADE ITS DEBUT AND WE WANT TO TALK ABOUT IT

HAPPY ANNIVERSARY BABIES!! The girls talk about the new direction of the podcast, men that took over their summer, the problems with parasocial relationships and their new collaborators BLACK LIGHT ANIMALS!!! Give them a listen on Spotify!

We HAD to talk about Denver and the out of this world experience the girls had meeting some of the most amazing artists. And of course, we couldn't have done the episode without bringing on our new friend Preston Knight! Arguably the best Billy Hargrove Cosplayer out there. Go Checkout his Spotify!

Sherm is joined by Sam and Coach on this edition of the SSF The guys kick around the upcoming high school football season as well as the UNH Wildcat fall campaign…the off season moves of the Celts and Bruins…the All Star break for MLB…Coach gives his take on the upcoming NASCAR action at N.H. Motor Speedway During the “Two Minute Drill” Sam gives his state of the Red Sox report…Coach gives kudos to the Spring sports teams and coaches, also Sherm updates the Quinn family participation in the upcoming Pan-Mass Challenge August 5th and 6th. You can support Brady & Joe Quinn at PNC.org for the benefit of Dana Farber Cancer Institute.

Joe Quinn has been on the pod before but we dive into the specifics of what his first RE deal looked like. It was a mix of Chick-fil-A and a Hobby Lobby. Episode Sponsored By Looking for fantastic remote workers? Call to Action Book a Call with Me Let's Buy a Business Newsletter 10 Step Video series to Finding a Company to Buy Let's Buy a Business Youtube Episode Resources Connect with Ryan Condie http://linkedin.com/in/ryancondie http://letsbuyabusiness.com/ https://forms.gle/RRcXpe3dK7pNGqv16 How to Buy Your First Small Business through Acquisition Entrepreneurship: https://letsbuyabusiness.com/course Stay Up to Date Newsletter: https://lbab.beehiiv.com/subscribe Connect with Joe on Linkedin https://www.linkedin.com/in/joequinn-vbc/ 

Boy was Dallas JAM PACKED with the best of Joe. We talk about going to

You can't get rid of us that easy Joe, you're a winner baby! There is absolutely no way with everything that's happened over the past few weeks, we could've waited for the new season. The girls talk about the MTV Movie and TV Awards, Pedro at the Met Gala, and Joe being casted as the one thing we never thought to fan cast him in....AN EMPEROR?! We've also launched a Patreon!! Make sure you stay till the end and get all the details! See you in Philly

The girls wrap up the season going over everything we have talked about this season and everything Joe... like how the Suffer brothers are giving us an Eddie prequel thereby giving us hope for an Eddie comeback.

Joe Quinn started his business acquisition search and then switched to buying $22M in real estate in 14 months. 14 deals in 14 months. Wild ride. We dive into… — How to Find a Mentor — How He Spotted Opportunities in Real Estate During His Search — How to Raise Money — Using W2 Knowledge to Launch His Career 2.0 Episode Sponsored By Looking for fantastic remote workers? Call to Action Book a Call with Me Let's Buy a Business Newsletter 10 Step Video series to Finding a Company to Buy Let's Buy a Business Youtube Episode Resources Connect with Ryan Condie http://linkedin.com/in/ryancondie http://letsbuyabusiness.com/ https://forms.gle/RRcXpe3dK7pNGqv16 How to Buy Your First Small Business through Acquisition Entrepreneurship: https://letsbuyabusiness.com/course Stay Up to Date Newsletter: https://lbab.beehiiv.com/subscribe Connect with Joe Quinn https://www.linkedin.com/in/joequinn-vbc/  

Our Main Man took some time to meet and take some photos with our friends in the UK. We talk to EMILY who attended the event. We also touch on Joe's take on social Media with our wonderful second guest, Brittany

Lets look at our current favorite stalker/murderer. Why are we so willing to forgive Joe Goldberg? Is it because his name is now Joe QUINN Goldberg? Maybe....

The Man.... The myth.... The Legend PAUL STEPHEN RUDD. Let's be honest who doesn't look at Paul and think to themselves "Yep there goes a good one"

On this episode of Our American Stories, here's Joe Quinn, a listener from West Virginia, with his story. Support the show (https://www.ouramericanstories.com/donate)See omnystudio.com/listener for privacy information.

Florence... Flo... Flossy Rose.... SHE IS A FORCE AND WE CAN'T GET ENOUGH OF HER. We talk facts, we talk fashion, we talk filmography!

Yep.... we're talking about the worlds favorite Chilean Daddy. Let's face it.... he's amazing. Talented, Funny, charming, what else could we ask for?

Surprise!! We're releasing a day early for Joe's Birthday!!! The girls sing happy birthday to Joe and unpack a few more of hi characters in addition to putting together some AQP theories!! PS - Peep the new intro song? What do we think?

THREE GUESTS??!?!?! The girls bring on their friends Arynn and Kel to talk about their experience with Fan Expo New Orleans. They also bring on JADE who was the most amazing Fan Expo team member who went viral just by being herself.

Two words.... JOE. KNOWS. The ladies went to Fan Expo New Orleans and told Joseph about his podcast themselves. You get the full story time from the ladies!

After a contentious opening to the US Congress 2023-2024 that saw Republican rebels force 15 (FIFTEEN!) votes for Speaker of the House, it's likely that Trump loyalists have stamped their influence on what is now a GOP-majority House of Representatives. While it's too early to know for sure, Joe Quinn speculates that this signals a sea-change in overall US government policy - one that will bring it in line with the direction President Trump had attempted to steer it towards: significantly...

After a contentious opening to the US Congress 2023-2024 that saw Republican rebels force 15 (FIFTEEN!) votes for Speaker of the House, it's likely that Trump loyalists have stamped their influence on what is now a GOP-majority House of Representatives. While it's too early to know for sure, Joe Quinn speculates that this signals a sea-change in overall US government policy - one that will bring it in line with the direction President Trump had attempted to steer it towards: significantly...

Hello chaps! Joe & Quinn are off this week, so Richard Land is stepping in with a very special presentation. It's OVP at their worst! Cheerio! For extra content:  patreon.com/ovppodcast Website: ovppodcast.com Twitter: @ovppodcast

This week on On the Rocks, host Emily King chats with Joe Quinn, founder and CTO of Davra. Emily and Joe dig into what exactly an "IOT" is, how the technology has progressed, and where its future in the mining industry might be heading. "The thing that I feel has worked best when you're trying to apply technology to manage risk at a mine site, ... it's better I think to start off with your risks. So, identify your risks and work backwards from that."Grab your Irish or Iced Coffee and tune in to the full episode below! Prospector is data mining the mining data, with access to over 10,000 mining projects worldwide! 

SURPRISE!!! There is no way we couldn've waited until next season to talk about everything that has developed over the last month. The girls talk about GQ, Tokyo Comic Con, Joe's new landed role in A Quiet Place: Day One, and all the other exciting this that have happened since the Season Finale!

The final episode of the first season! We have absolutely loved doing with for and with you. Next season we are coming at you with MORE guests, MORE Female Gaze worthy people and JUST ALL AROUND MORE!!! WE LOVE YOU!!

IT'S A JAIME CAMPBELL BOWER TAKEOVER EPISODE! We know him, we love him, he's our favorite friendly orderly so it only makes sense that we dedicate our 10th episode to him. The girls also talk about Joe's accomplishment in being recognized as Variety's top 10 actors to watch in 2022 event at the Newport Beach Film Festival.

Let's talk Dior, A good ole bucket of Ice water of a reality check and the Bromances Joe has made since this roller coaster has started

The ladies welcome Chole Miller on the show! They also talk about the JQ at Paris Fashion week, Irish Mike and let's not forget the massive disappointment that was TUDUM

Arguably the most unhinged episode the girls have released to date. CAN WE TALK ABOUT ESQUIRE SINGAPORE?! Also why are all of joes characters so tragic?

THIS EPISODE IS DEDICATED TO JOE'S TRUE No. 1 FAN RYAN!!!!! The girls talk about the influx of Joe content that came from wonderland magazine, blissfully unaware of the Esquire video that would come out just a few hours after recording this episode. They also talk about role's they would like to see him in.

WE HAVE OUR FIRST GUEST!!!!! Shannon, Laura and Danielle reminisce on their first celebrity hyperfixation. They also touch on some of the toxic behavior surrounding Joe's Fandom. Also... peep the new logo ;)

Have you tasted the World's Best Irish Cream Liqueur? Join us as we discuss the creation and distribution of Five Farms Irish Cream, the world's first farm-to-table Irish Cream liqueur.Special guests Johnny Harte, Joe Quinn, and Rachel Dignan chat through all aspects of developing and launching a new brand.©️2023 Holladay Distillery Weston, MO. Drink Responsibly. Drive Responsibly.

The ladies unpack Fan Expo Canada!

Welcome to the place where we get to let our geek flags fly and talk about all things geek. Basically a fuzzy guide to life, the universe, and everything but mostly geek stuff. This is a look into the world of geekdom and some geek news, comics, The Simpsons, Star Wars, and whatever randomness finds its way onto the recording. This episode of the podcast includes: Shang-Chi director lands Avengers: The Kang Dynasty gig Russo Bros not directing Secret Wars Weird: The Al Yankovic Story poster & release date - Nov 4th on Roku RIP Nichelle Nichols Krysten Ritter headlining AMC Orphan Black sequel The Flash on CW ending with Season 9 Cut of Breaking Bad with Thanos in Endgame Rumor of Jon Bernthal returning as Frank Castle in Daredevil Reborn Zombie Strange Blue-Ray covers for Dr. SitMoM 30th anniversary of Buffy the Vampire Slayer Batgirl movie shelved with no release plans, memes, and leaked BTS footage Marvel announces new Thunderbolts comic team for August Official Andor Trailer - 3 episodes on Sept 21 Cars on the Road trailer Marvel officially confirms Secret Invasion as crossover event Marvel casts RuPaul Drag Race non-binary actor Shea Coulee in Ironheart Image of Arrow protecting Blue Beetle Kevin Smith announces Smodcastle Cinemas and View Askewniversity Video of Eddie Munson actor Joe Quinn meeting Metallica Funny meme of Spidey and Cap banter LEGO Avatar sets First look teaser for National Treasure: Edge of History series First look at Marvel's Moon Girl and Devil Dinosaur - 2023 William Shatner in MOTU: Revolution Amazon's Wheel of Time renewed for 3rd season Mike Judge says King of the Hill has a very good chance of coming back TMNT/Power Rangers comic gets a sequel from BOOM! Spongebob Squarepants crossover event Marvel Zombies Real-life Infinity Gauntlet with stones worth 25 million Walking Dead spin-off with Rick and Michonne in 2023 Keanu Reeves' BRZRKR anime gets two seasons on Netflix Batman/Spawn crossover comic by Todd McFarlane and Greg Capullo John Boyega re: toxic Star Wars fans Andor actress Fiona Shaw says show is a galactic send-up of the Trump era Tony Gilroy says Andor did not use the Volume at all Aquaman 2 will see return of Batfleck Rick Riordan says Percy Jackson show will probably stream on Disney+ in 2024 KOTOR remake paused indefinitely Disney+ working on an Eragon series Keanu Reeves to star in Devil in the White City series on Hulu David Krumholtz returning as Bernard in ‘The Santa Clauses' on Disney+ Spider-Man: Freshman Year details Avatar: TLA casts original voice actor James Sie as Cabbage Merchant Kevin Feige confirms that Spidey will continue in MCU as street level hero Oscar Isaac and director Mohammed Diab tease Moon Knight S2 on TikTok Joker: Folie à deux is set for Oct 4, 2022 Warner Bros. Discovery CEO David Zaslav re: DC's plan WB has scrapped planned Supergirl movie Report of 3.42 billion loss in 2d quarter for Warner Discovery and what that means Congrats on completing Level 306 of the podcast! Think positive, test negative, stay safe, wash your hands, wear a mask, and good luck out there. Twitter / Instagram (@wookieeriot). Email: laughitupfuzzballpodcast@gmail.com. Facebook (https://www.facebook.com/groups/1879505335626093). Merch: teepublic.com/user/laugh-it-up-fuzzball. Subscribe & rate wherever you listen. May the force be with us all, thanks for stopping by, you stay classy, be excellent to each other and party on dudes! TTFN… Wookiee out! --- Send in a voice message: https://anchor.fm/laugh-it-up-fuzzball/message Support this podcast: https://anchor.fm/laugh-it-up-fuzzball/support

This week, Princess and Tessa complete their Stranger Things 4 conversation, a bittersweet ending to our current Stranger Era. They play a spicy game of kiss/marry/kill, make mixtapes for all of our beloved children, and discuss all of their juicy theories for the series finale.!!SPOILER WARNING!! for episodes 8 and 9 of Stranger Things 4!

In this week's episode, we talk about season 4 of Stranger Things, our love for Joe Quinn, and Rosanna shares her new fear.  --- Send in a voice message: https://podcasters.spotify.com/pod/show/simptoms/message

Two months into the most politically and militarily seismic event since World War Two, is Russia 'winning' or 'losing' in Ukraine? And can this complicated situation really be reduced to such an oversimplified question and answer? This week on NewsReal, Joe Quinn answers listeners' questions about the war in Ukraine and its global ramifications, explaining what probably happened to the Moskva Russian ship, what will likely happen to Ukrainian refugees, the probability that Ukraine will be...

Two months into the most politically and militarily seismic event since World War Two, is Russia 'winning' or 'losing' in Ukraine? And can this complicated situation really be reduced to such an oversimplified question and answer? This week on NewsReal, Joe Quinn answers listeners' questions about the war in Ukraine and its global ramifications, explaining what probably happened to the Moskva Russian ship, what will likely happen to Ukrainian refugees, the probability that Ukraine will be...

 Award-winning ABM strategist shares his decade-long journey with ABM and advice for getting started or improving your programs. Joe Quinn, Senior Account-Based Marketing (ABM) Manager at Salesforce-Tableau and former ABM Leader at NI (National Instruments) has spent the past decade learning, inventing, measuring, and improving on all things ABM. Joe and his team at NI were recognized with an ABM Program of the Year award by the Flip my Funnel organization, and he's tasked with scaling ABM marketing efforts at Salesforce-Tableau.Many companies may think they need to be doing ABM given how buzzy it is in our marketing world, but here are a few criteria Joe suggests using to assess whether or not your organization is ready for ABM:Are there dedicated sales resources to named accounts? Are those accounts tiered?Is executive leadership on board with ABM? Is there a salesperson (or salespeople) willing to devote time and energy as a partner with marketing?Does the company recognize and support resource tradeoffs between volume-based lead generation versus strategic relationship development?If all signs look positive, Joe suggests a multi-phase ABM framework with associated metrics, including account research and prioritization, content development, tailored tactical execution, and closed-loop reporting.During the episode Joe shares some of his award-winning ABM tactics, including case study briefs, customized LinkedIn introductions from Account Managers, and contact acquisition. We also touch on the role of technology to help enhance, automate and measure ABM initiatives -- and when these should and should not integrate into the CRM or other platforms in use.For show links and more, visit the Content Marketing, Engineered podcast blog https://bit.ly/CMEPodcast Learn more about TREW Marketing https://www.trewmarketing.com Order the book! Content Marketing, Engineered https://bit.ly/contentmktgeng

This week we have a very special gal joining us on the pod, Rosemary Joaquin (pronounced Joe-Quinn, not like Joaquin Phoenix, don't get it twisted). Rose is a D.C. native who is now in Nashville grinding it out as a singer and songwriter. We get to know Rose and hear about her journey to Music City. You can check her out on social media @rosemaryjoaquin and find her music on Spotify here: https://open.spotify.com/artist/5siWl4GNJu9rBMoexPD9R6?si=RKdN5fbJTf6whv8IUGXpeg-Host social handles: @brookeduvee @aaronclafton @kari_c00per-Find us on Instagram, Twitter, TikTok, and Facebook: @threetoomanypodIf you want to submit a funny story, ask questions of the hosts, or give a shout out to a fellow listener, shoot us an email: threetoomanypod@gmail.com